Literature DB >> 19147366

Modification of the furan ring of salvinorin A: identification of a selective partial agonist at the kappa opioid receptor.

Cécile Béguin1, Katharine K Duncan, Thomas A Munro, Douglas M Ho, Wei Xu, Lee-Yuan Liu-Chen, William A Carlezon, Bruce M Cohen.   

Abstract

In an effort to find novel agents which selectively target the kappa opioid receptor (KOPR), we modified the furan ring of the highly potent and selective KOPR agonist salvinorin A. Introduction of small substituents at C-16 was well tolerated. 12-epi-Salvinorin A, synthesized in four steps from salvinorin A, was a selective partial agonist at the KOPR. No clear SAR patterns were observed for C-13 aryl ketones. Introducing a hydroxymethylene group between C-12 and the furan ring was tolerated. Small C-13 esters and ethers gave weak KOPR agonists, while all C-13 amides were inactive. Finally, substitution of oxadiazoles for the furan ring abolished affinity for the KOPR. None of the compounds displayed any KOPR antagonism or any affinity for mu or delta opioid receptors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19147366      PMCID: PMC2680211          DOI: 10.1016/j.bmc.2008.12.012

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  28 in total

1.  5'-Guanidinonaltrindole, a highly selective and potent kappa-opioid receptor antagonist.

Authors:  R M Jones; P S Portoghese
Journal:  Eur J Pharmacol       Date:  2000-05-12       Impact factor: 4.432

Review 2.  The mesolimbic dopamine reward circuit in depression.

Authors:  Eric J Nestler; William A Carlezon
Journal:  Biol Psychiatry       Date:  2006-03-29       Impact factor: 13.382

3.  Antinociceptive profile of salvinorin A, a structurally unique kappa opioid receptor agonist.

Authors:  Christopher R McCurdy; Kenneth J Sufka; Grant H Smith; Jason E Warnick; Marcelo J Nieto
Journal:  Pharmacol Biochem Behav       Date:  2006-01-23       Impact factor: 3.533

4.  Asymmetric synthesis of salvinorin A, a potent kappa opioid receptor agonist.

Authors:  Jonathan R Scheerer; Jonathan F Lawrence; Grace C Wang; David A Evans
Journal:  J Am Chem Soc       Date:  2007-06-30       Impact factor: 15.419

5.  Studies toward the pharmacophore of salvinorin A, a potent kappa opioid receptor agonist.

Authors:  Thomas A Munro; Mark A Rizzacasa; Bryan L Roth; Beth A Toth; Feng Yan
Journal:  J Med Chem       Date:  2005-01-27       Impact factor: 7.446

6.  Comparison of pharmacological activities of three distinct kappa ligands (Salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo.

Authors:  Yulin Wang; Kang Tang; Saadet Inan; Daniel Siebert; Ulrike Holzgrabe; David Y W Lee; Peng Huang; Jian-Guo Li; Alan Cowan; Lee-Yuan Liu-Chen
Journal:  J Pharmacol Exp Ther       Date:  2004-09-21       Impact factor: 4.030

7.  Anxiolytic-like effects of kappa-opioid receptor antagonists in models of unlearned and learned fear in rats.

Authors:  Allison T Knoll; Edward G Meloni; James B Thomas; F Ivy Carroll; William A Carlezon
Journal:  J Pharmacol Exp Ther       Date:  2007-09-06       Impact factor: 4.030

8.  Binaltorphimine and nor-binaltorphimine, potent and selective kappa-opioid receptor antagonists.

Authors:  P S Portoghese; A W Lipkowski; A E Takemori
Journal:  Life Sci       Date:  1987-03-30       Impact factor: 5.037

9.  Pharmacological properties of JDTic: a novel kappa-opioid receptor antagonist.

Authors:  Ivy Carroll; James B Thomas; Linda A Dykstra; Arthur L Granger; Richard M Allen; James L Howard; Gerald T Pollard; Mario D Aceto; Louis S Harris
Journal:  Eur J Pharmacol       Date:  2004-10-06       Impact factor: 4.432

10.  The plant-derived hallucinogen, salvinorin A, produces kappa-opioid agonist-like discriminative effects in rhesus monkeys.

Authors:  Eduardo R Butelman; Todd J Harris; Mary Jeanne Kreek
Journal:  Psychopharmacology (Berl)       Date:  2003-10-30       Impact factor: 4.530

View more
  16 in total

Review 1.  Clerodane diterpenes: sources, structures, and biological activities.

Authors:  Rongtao Li; Susan L Morris-Natschke; Kuo-Hsiung Lee
Journal:  Nat Prod Rep       Date:  2016-07-18       Impact factor: 13.423

2.  Semisynthesis and Kappa-Opioid Receptor Activity of Derivatives of Columbin, a Furanolactone Diterpene.

Authors:  Anil Yilmaz; Rachel Saylor Crowley; Alexander M Sherwood; Thomas E Prisinzano
Journal:  J Nat Prod       Date:  2017-07-18       Impact factor: 4.050

Review 3.  Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin A.

Authors:  Christopher W Cunningham; Richard B Rothman; Thomas E Prisinzano
Journal:  Pharmacol Rev       Date:  2011-03-28       Impact factor: 25.468

4.  Differential signaling properties at the kappa opioid receptor of 12-epi-salvinorin A and its analogues.

Authors:  Cécile Béguin; Justin Potuzak; Wei Xu; Lee-Yuan Liu-Chen; John M Streicher; Chad E Groer; Laura M Bohn; William A Carlezon; Bruce M Cohen
Journal:  Bioorg Med Chem Lett       Date:  2011-12-07       Impact factor: 2.823

Review 5.  A review of salvinorin analogs and their kappa-opioid receptor activity.

Authors:  Jeremy J Roach; Ryan A Shenvi
Journal:  Bioorg Med Chem Lett       Date:  2018-03-12       Impact factor: 2.823

6.  Semisynthetic neoclerodanes as kappa opioid receptor probes.

Authors:  Kimberly M Lovell; Tamara Vasiljevik; Juan J Araya; Anthony Lozama; Katherine M Prevatt-Smith; Victor W Day; Christina M Dersch; Richard B Rothman; Eduardo R Butelman; Mary Jeanne Kreek; Thomas E Prisinzano
Journal:  Bioorg Med Chem       Date:  2012-03-01       Impact factor: 3.641

7.  General method for synthesis of 2-heterocyclic N-methyliminodiacetic acid boronates.

Authors:  Graham R Dick; David M Knapp; Eric P Gillis; Martin D Burke
Journal:  Org Lett       Date:  2010-05-21       Impact factor: 6.005

8.  Synthetic studies of neoclerodane diterpenes from Salvia divinorum: role of the furan in affinity for opioid receptors.

Authors:  Denise S Simpson; Kimberly M Lovell; Anthony Lozama; Nina Han; Victor W Day; Christina M Dersch; Richard B Rothman; Thomas E Prisinzano
Journal:  Org Biomol Chem       Date:  2009-07-14       Impact factor: 3.876

9.  Relative Timing Between Kappa Opioid Receptor Activation and Cocaine Determines the Impact on Reward and Dopamine Release.

Authors:  Elena H Chartoff; Shayla R Ebner; Angela Sparrow; David Potter; Phillip M Baker; Michael E Ragozzino; Mitchell F Roitman
Journal:  Neuropsychopharmacology       Date:  2015-08-04       Impact factor: 7.853

Review 10.  Chemical methods for the synthesis and modification of neoclerodane diterpenes.

Authors:  Anthony Lozama; Thomas E Prisinzano
Journal:  Bioorg Med Chem Lett       Date:  2009-07-17       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.